JNJ-26990990: Difference between revisions
Content deleted Content added
m Stub sorting and placement of stub template(s): anticonvulsant-stub. See approval. Report errors and suggestions at User talk:PotatoBot. |
Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Drugbox validation |
||
| Line 1: | Line 1: | ||
{{Drugbox |
{{Drugbox |
||
| verifiedrevid = |
| verifiedrevid = 444297842 |
||
| name = JNJ-26990990 |
| name = JNJ-26990990 |
||
| IUPAC_name = 3-[(Sulfamoylamino)methyl]-1-benzothiophene |
| IUPAC_name = 3-[(Sulfamoylamino)methyl]-1-benzothiophene |
||
| Line 34: | Line 34: | ||
| ATC_suffix = |
| ATC_suffix = |
||
| PubChem = 11687376 |
| PubChem = 11687376 |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|||
| DrugBank = |
| DrugBank = |
||
| synonyms = ''N''-((Benzo[''b'']thien-3-yl)methyl)sulfamide |
| synonyms = ''N''-((Benzo[''b'']thien-3-yl)methyl)sulfamide |
||
Revision as of 14:49, 10 September 2011
 | |
| Clinical data | |
|---|---|
| Other names | N-((Benzo[b]thien-3-yl)methyl)sulfamide |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C9H10N2O2S2 |
| Molar mass | 242.3179 g/mol |
| (verify) | |
JNJ-26990990 is a broad-spectrum anticonvulsant drug currently under development by Janssen Pharmaceutica as a second-generation followup to the marketed drug topiramate.[1][2] It was designed to have the same anticonvulsant effects as topirimate, but without the side effects associated with topiramate's carbonic anhydrase inhibition.[1] It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression.[3]
JNJ-26990990 entered phase II clinical trials in October 2007.[4]
References
- ^ a b Michael H. Parker; et al. (2009). "Novel, Broad-Spectrum Anticonvulsants Containing a Sulfamide Group: Advancement of N-((Benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into Human Clinical Studies". Journal of Medicinal Chemistry. 52 (23): 7528–36. doi:10.1021/jm801432r. PMID 19388676.
{{cite journal}}: Unknown parameter|author-separator=ignored (help) - ^ WO patent 2006023861, Parker, Michael H.; Reitz, Allen B.; Maryanoff, Bruce E., "Preparation of benzo-fused heteroaryl sulfamide derivatives for the treatment of epilepsy and related disorders", issued 2006-03-02, assigned to Janssen Pharmaceutica
- ^ "JNJ 26990990 Johnson & Johnson developing anticonvulsant Johnson & Johnson preclinical data". R & D Focus Drug News. September 22, 2008.
- ^ János Fischer and C. Robin Ganellin (2010). "Chapter 2. Standalone Drugs". Analogue-Based Drug Discovery II. doi:10.1002/9783527630035.ch2.
 | This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |